Condition
ErbB2-Positive Stage I-III Breast Cancer
Total Trials
1
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
Treatment Research
1 treatments under study, led by Paclitaxelcarboplatinlapatinib
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 2 (1)
Trial Status
Unknown1
Clinical Trials (1)
Research Network
Common Treatments
- Paclitaxelcarboplatinlapatinib1
Active Sponsors
- National University Hospital, Singapore1
- National Cancer Centre, Singapore1
Top Investigators
National University Hospital, Singapore